YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer

Metastatic castration-resistant prostate cancer (mCRPC) is a malignant and lethal disease caused by relapse after androgen-deprivation (ADT) therapy. Since enzalutamide is innovated and approved by US FDA as a new treatment option for mCRPC patients, drug resistance for enzalutamide is a critical is...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hsiu-Chi, Ou, Chien-Hui, Huang, Yun-Chen, Hou, Pei-Chi, Creighton, Chad J., Lin, Yi-Syuan, Hu, Che-Yuan, Lin, Shih-Chieh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016667/
https://www.ncbi.nlm.nih.gov/pubmed/33664454
http://dx.doi.org/10.1038/s41388-021-01718-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8016667/
https://www.ncbi.nlm.nih.gov/pubmed/33664454
http://dx.doi.org/10.1038/s41388-021-01718-4

Ejemplares similares